Importer of Controlled Substances Application: Sharp Clinical Services, LLC
Published Date: 2/2/2026
Notice
Summary
Sharp Clinical Services, LLC wants to become an official importer of certain controlled substances, including some Schedule I drugs like Gamma Hydroxybutyric Acid and MDMA. This affects companies involved in drug manufacturing and regulation, who can comment or request a hearing by March 4, 2026. No fees or immediate changes yet, but this step could impact drug supply chains soon.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
Import Use Limited; No Commercial Finished Drugs
The company plans to import the listed substances for distribution and clinical trials only; the registration would not authorize any other activities for these drug codes. The authorization explicitly will not extend to importing Food and Drug Administration‑approved or non‑approved finished dosage forms for commercial sale.
New Importer Seeks Schedule I Registration
Sharp Clinical Services, LLC applied on January 9, 2026 to be registered as an importer of four Schedule I controlled substances: Gamma Hydroxybutyric Acid (code 2010), 3,4‑Methylenedioxy‑methamphetamine (MDMA, code 7405), 5‑Methoxy‑N‑N‑dimethyltryptamine (code 7431), and Psilocybin (code 7437). Registered bulk manufacturers and other interested parties may submit comments or request a hearing on the application on or before March 4, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in